deltatrials
Terminated PHASE1 INTERVENTIONAL 2-arm NCT06780033

A Study to Evaluate ART101 in Adult Participants With Hypertension

A Phase 1, Randomized, Double-blind, Placebo Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ART101 in Adult Participants With Hypertension.

Sponsor: Arnatar Therapeutics, Inc.

Conditions Hypertension
Interventions ART-101 - SAD Placebo
Updated 4 times since 2025 Last updated: Sep 17, 2025 Started: Mar 17, 2025 Primary completion: Apr 30, 2025 Completion: Apr 30, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

At Sponsor's Request

Other Hypertension trials with similar outcome

Browse all Hypertension trials

This PHASE1 trial investigates Hypertension and is currently terminated or withdrawn. Arnatar Therapeutics, Inc. leads this study, which shows 4 recorded versions since 2025 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

~Feb 2025 – ~Mar 2025 · 28 days · monthly snapshot~Mar 2025 – ~Apr 2025 · 31 days · monthly snapshot~Apr 2025 – ~Oct 2025 · 6 months · monthly snapshotRecruiting~Oct 2025 – present · 9 months · monthly snapshotTerminated

Change History

4 versions recorded

  1. Oct 2025 — Present [monthly]

    Terminated PHASE1

    Status: Recruiting → Terminated

  2. Apr 2025 — Oct 2025 [monthly]

    Recruiting PHASE1

  3. Mar 2025 — Apr 2025 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  4. Feb 2025 — Mar 2025 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Arnatar Therapeutics, Inc.
Data source: Arnatar Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations